Korean J Schizophr Res.  2012 Jun;15(1):46-49. 10.16946/kjsr.2012.15.1.46.

A Case of Blonanserin-Induced Mania in Schizophrenia

• Park SY
• Kim YK
• Lee JH

• KMID: 1790747
• DOI: http://doi.org/10.16946/kjsr.2012.15.1.46

Abstract

Schizophrenia is a psychiatric disease which requires a long term treatment. Thus, patient's therapeutic compliance can be very crucial to the disease's prognosis. Moreover, the adverse effects of drugs are also important to determine the patient's therapeutic compliance. The atypical antipsychotic drugs have been improved in the way to strengthen therapeutic effects and to reduce adverse effects. Blonanserin, an atypical antipsychotic, is a selective serotonin-dopamine agonist which blocks the dopamine D2/D3 receptors and serotonin 5-HT2A receptor. Blonanserin is well known to include parkinsonism, akathisia and insomnia. In this case report, Blonanserin treatment was given to patients who admitted to the closed ward due to psychotic symptoms such as idea of reference, persecutory delusion, auditory hallucination and blunted affect. The patients showed manic symptoms including elated mood, talkativeness, hyperactivity after the increase of Blonanserin dose up to 24 mg. Such manic symptoms were improved after Blonanserin dose was decreased to 16 mg. Many researches have reported newly-evoked manic/hypomanic episodes in schizophrenic patients after the use of atypical antipsychotics such as Risperidone, Olanzapine and Ziprasidone. However, there is no report of Blonanserin-induced manic/hypomanic episode. Therefore, further study is necessary to evaluate the manic/hypomanic episodes which are thought to be the adverse effects of Blonanserin.

Keyword

Blonanserin; Schizophrenia; Atypical antipsychotics; Mania

MeSH Terms

Antipsychotic Agents
Benzodiazepines
Bipolar Disorder
Compliance
Delusions
Dopamine
Hallucinations
Humans
Parkinsonian Disorders
Piperazines
Piperidines
Prognosis
Psychomotor Agitation
Receptor, Serotonin, 5-HT2A
Risperidone
Schizophrenia
Serotonin
Sleep Initiation and Maintenance Disorders
Thiazoles
Antipsychotic Agents
Benzodiazepines
Dopamine
Piperazines
Piperidines
Receptor, Serotonin, 5-HT2A
Risperidone
Serotonin
Thiazoles

Figure

• 

  Fig. 1 Young Mania Rating Scale (YMRS) Scale Change correspond to Blonanserin dose. HD : hospitalized day.

• 

  Fig. 2 Positive and Negative Syndrome Scale (PANSS) Change correspond to Blonanserin dose (mg). HD : hospitalized day.

Reference

1. . Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). 2009. London: National Institute for Health and Clinical Excellence.

2. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004. 161:1–56.

3. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007. 21:911–936.

4. Yang J, Bahk WM, Cho HS, Jeon YW, Jon DI, Jung HY, et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010. 33:169–175.

5. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010. 24:65–84.

6. Ishibashi T, Nishikawa H, Une T, Nakamura H. [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia]. Nihon Yakurigaku Zasshi. 2008. 132:351–360.

7. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009. 23:615–625.

8. Ohno Y, Okano M, Imaki J, Tatara A, Okumura T, Shimizu S. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. Pharmacol Biochem Behav. 2010. 96:175–180.

9. Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry. 2000. 61:649–655.

10. Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry. 2004. 65:1537–1545.

11. Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related? J Clin Psychiatry. 1998. 59:85–86.

12. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT (2A) and D (2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001. 76:1521–1531.